Get the Stockscreener App
6.61
2.94%
-0.20
Arvinas Inc stock is traded at $6.61, with a volume of 1.63M.
It is down -2.94% in the last 24 hours and down -1.78% over the past month.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.
See More
Previous Close:
$6.81
Open:
$6.78
24h Volume:
1.63M
Relative Volume:
0.60
Market Cap:
$563.49M
Revenue:
$161.10M
Net Income/Loss:
$-308.60M
P/E Ratio:
-1.4154
EPS:
-4.67
Net Cash Flow:
$-259.90M
1W Performance:
-14.38%
1M Performance:
-1.78%
6M Performance:
-75.64%
1Y Performance:
-79.31%
1-Day Range:
$6.58
$6.89
1-Week Range:
$6.505
$7.91
52-Week Range:
$5.935
$37.38
Arvinas Inc Stock (ARVN) Company Profile
Name
Arvinas Inc
Sector
Industry
Phone
203-535-1456
Address
395 WINCHESTER AVE, NEW HAVEN, CT
Compare ARVN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ARVN
Arvinas Inc
|
6.61 | 563.49M | 161.10M | -308.60M | -259.90M | -4.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.99 | 128.84B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
527.78 | 65.38B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
549.65 | 39.67B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.15 | 33.82B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
231.99 | 27.60B | 3.81B | -644.79M | -669.77M | -6.24 |
Arvinas Inc Stock (ARVN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-05-25 | Downgrade | Truist | Buy → Hold |
| May-02-25 | Downgrade | Jefferies | Buy → Hold |
| May-02-25 | Downgrade | TD Cowen | Buy → Hold |
| Mar-13-25 | Downgrade | Goldman | Buy → Neutral |
| Mar-12-25 | Downgrade | Wedbush | Outperform → Neutral |
| Mar-11-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Dec-10-24 | Initiated | BTIG Research | Buy |
| Nov-18-24 | Initiated | Stephens | Overweight |
| Feb-28-24 | Reiterated | Oppenheimer | Outperform |
| Feb-14-24 | Downgrade | Citigroup | Buy → Neutral |
| Feb-01-24 | Initiated | Goldman | Buy |
| Dec-19-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Dec-06-23 | Upgrade | Jefferies | Hold → Buy |
| Nov-20-23 | Upgrade | Guggenheim | Neutral → Buy |
| Oct-23-23 | Upgrade | Wedbush | Neutral → Outperform |
| Jun-26-23 | Resumed | Oppenheimer | Outperform |
| Jan-12-23 | Downgrade | Guggenheim | Buy → Neutral |
| Jan-03-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Sep-09-22 | Initiated | Barclays | Overweight |
| Jun-21-22 | Initiated | Jefferies | Hold |
| May-09-22 | Downgrade | Wedbush | Outperform → Neutral |
| Apr-28-22 | Initiated | Credit Suisse | Outperform |
| Apr-06-22 | Initiated | Morgan Stanley | Equal-Weight |
| Feb-11-22 | Resumed | BMO Capital Markets | Outperform |
| Feb-10-22 | Initiated | Wells Fargo | Overweight |
| Jan-19-22 | Initiated | Goldman | Buy |
| Dec-07-21 | Initiated | Cowen | Outperform |
| Oct-14-21 | Initiated | SVB Leerink | Outperform |
| Sep-30-21 | Initiated | Stifel | Buy |
| Sep-09-21 | Initiated | BofA Securities | Buy |
| May-21-21 | Initiated | UBS | Buy |
| Apr-21-21 | Initiated | Truist | Buy |
| Mar-31-21 | Initiated | BMO Capital Markets | Outperform |
| Dec-14-20 | Upgrade | Oppenheimer | Perform → Outperform |
| Jun-01-20 | Upgrade | Citigroup | Neutral → Buy |
| May-12-20 | Initiated | Oppenheimer | Perform |
| Dec-19-19 | Initiated | H.C. Wainwright | Buy |
| Nov-25-19 | Initiated | Guggenheim | Buy |
| Oct-24-19 | Upgrade | Goldman | Neutral → Buy |
| Sep-25-19 | Initiated | Wedbush | Outperform |
| Sep-12-19 | Initiated | BMO Capital Markets | Outperform |
| Aug-06-19 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-05-19 | Downgrade | Citigroup | Buy → Neutral |
| Apr-12-19 | Initiated | Evercore ISI | Outperform |
| Oct-22-18 | Initiated | Citigroup | Buy |
| Oct-22-18 | Initiated | Goldman | Neutral |
| Oct-22-18 | Initiated | Piper Jaffray | Overweight |
View All
Arvinas Inc Stock (ARVN) Latest News
(ARVN) Investment Analysis - news.stocktradersdaily.com
Arvinas, Inc. Investigated by Shareholder Rights AdvocatesInvestors Should Contact Levi & Korsinsky Regarding Potential Securities Law ViolationsARVN - ACCESS Newswire
Morgan Stanley Adjusts Price Target for Arvinas (ARVN) | ARVN Stock News - GuruFocus
Algert Global LLC Has $3.95 Million Stock Position in Arvinas, Inc. (NASDAQ:ARVN) - MarketBeat
Morgan Stanley Cuts Price Target on Arvinas to $11 From $12, Keeps Equalweight Rating - marketscreener.com
Dimensional Fund Advisors LP Raises Position in Arvinas, Inc. (NASDAQ:ARVN) - Defense World
Short Interest in Arvinas, Inc. (NASDAQ:ARVN) Expands By 21.0% - MarketBeat
FY2025 EPS Estimates for Arvinas Lifted by Cantor Fitzgerald - Defense World
ArrowMark Colorado Holdings LLC Buys 532,105 Shares of Arvinas, Inc. (NASDAQ:ARVN) - MarketBeat
Levi & Korsinsky Announces an Investigation on Behalf of Arvinas, Inc. (ARVN) Shareholders Who May Have Been Affected by Fraud - ACCESS Newswire
ARVINAS ALERT: Bragar Eagel & Squire, P.C. is Investigating - GlobeNewswire
Boxer Capital Management LLC Purchases Shares of 1,058,614 Arvinas, Inc. (NASDAQ:ARVN) - MarketBeat
ARVINAS ALERT: Bragar Eagel & Squire, P.C. is Investigating Arvinas, Inc. on Behalf of Arvinas Stockholders and Encourages Investors to Contact the Firm - TradingView
Citigroup Cuts Arvinas (NASDAQ:ARVN) Price Target to $9.50 - MarketBeat
ARVN ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Arvinas, Inc. - ACCESS Newswire
ARVN ALERT- Levi & Korsinsky Has Commenced an Investigation on Behalf of Arvinas, Inc. Shareholders Who Lost Money - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Encourages Arvinas, Inc. (ARVN) Investors to Inquire about Securities Investigation - ACCESS Newswire
Arvinas, Inc. (ARVN) Investors May Be Able to Recover Losses By Reaching Out To Block & Leviton Regarding Securities Fraud Investigation - TradingView
BMO Capital Markets Issues Pessimistic Forecast for Arvinas (NASDAQ:ARVN) Stock Price - MarketBeat
Arvinas' (ARVN) "Hold" Rating Reiterated at Truist Financial - MarketBeat
PROTAC Market to See Booming Growth 2025-2032 | Arvinas, Celgene, Nurix Therapeutics, Hinova Pharmaceuticals - openPR.com
Arvinas (NASDAQ:ARVN) Earns "Hold" Rating from Jefferies Financial Group - MarketBeat
HC Wainwright Issues Pessimistic Forecast for Arvinas (NASDAQ:ARVN) Stock Price - MarketBeat
Piper Sandler Reiterates Overweight Rating for Arvinas (NASDAQ:ARVN) - MarketBeat
Arvinas (NASDAQ:ARVN) and Mustang Bio (NASDAQ:MBIO) Financial Contrast - Defense World
Kirby McInerney LLP Announces Investigation of Claims Against FTI Consulting, Inc. (FCN) on Behalf of Investors - GlobeNewswire Inc.
Arvinas, Inc. Investigation Ongoing: Contact Levi & Korsinsky to Discuss Your RightsARVN - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arvinas, Inc.ARVN - PR Newswire
Arvinas, Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud AllegationsARVN - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Arvinas, Inc. (ARVN) And Encourages Investors to Reach Out - ACCESS Newswire
Arvinas, Inc. (NASDAQ:ARVN) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Arvinas targets regulatory filing for Vepdegestrant in metastatic breast cancer by 2025 - msn.com
Arvinas (ARVN) Price Target Adjustment by Citigroup | ARVN Stock News - GuruFocus
Kirby McInerney LLP Announces Investigation of Potential Claims Against Arvinas, Inc. (ARVN) on Behalf of Investors - GlobeNewswire
Arvinas (NASDAQ:ARVN) Price Target Cut to $9.50 by Analysts at Citigroup - Defense World
Arvinas (NASDAQ:ARVN) Price Target Lowered to $10.00 at BMO Capital Markets - Defense World
Arvinas, Inc. (NASDAQ:ARVN) Shares Purchased by Schonfeld Strategic Advisors LLC - MarketBeat
Arvinas (ARVN) Sees Analyst Downgrade and Significant Price Targ - GuruFocus
ARVN: BMO Capital Maintains Rating While Lowering Price Target | - GuruFocus
Where Arvinas Stands With Analysts - Benzinga
Citi cuts Arvinas stock price target to $9.50, keeps neutral rating - Investing.com Nigeria
Citi cuts Arvinas stock price target to $9.50, keeps neutral rating By Investing.com - Investing.com South Africa
Arvinas (ARVN) Downgraded by Truist Amid Market Concerns | ARVN Stock News - GuruFocus
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arvinas, ... - Bluefield Daily Telegraph
ARVN: BMO Capital Maintains Rating While Lowering Price Target | ARVN Stock News - GuruFocus
Arvinas (NASDAQ:ARVN) Releases Earnings Results - MarketBeat
Arvinas (ARVN) Target Price Lowered by Citi Amid Pipeline Develo - GuruFocus
Truist Downgrades Arvinas to Hold From Buy, Cuts Price Target to $11 From $21 - marketscreener.com
Arvinas stock rating cut, price target slashed to $11 at Truist - Investing.com Australia
Arvinas (ARVN) Expected to Announce Earnings on Thursday - MarketBeat
Arvinas: Yet Another Biotech Trading Below Net Cash, But It's Only A Mild Bull Case - Seeking Alpha
Arvinas Inc Stock (ARVN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.84%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):